AI English summary of an SEC filing — figures as filed
Edwards Lifesciences EWEdwards Lifesciences said stockholders approved the amendment and restatement of its Long-Term Stock Incentive Compensation Program at the 2026 Annual Meeting of Stockholders. The total number of shares of Edwards common stock available for issuance under the program increased by 7,000,000 shares to a new total share limit of 341,500,000 shares.
Key points
AI summaryEdwards Lifesciences said stockholders approved the amendment and restatement of its Long-Term Stock Incentive Compensation Program at the 2026 Annual Meeting of Stockholders. The total number of shares of Edwards common stock available for issuance under the program increased by 7,000,000 shares to a new total share limit of 341,500,000 shares.
The company disclosed voting results on Proposal 4, the approval of the Amended and Restated Long-Term Stock Incentive Compensation Program, with 456,675,201 votes for, 19,210,539 votes against, 0 abstentions and 27,211,476 broker non-votes.
Edwards Lifesciences said all 9 director nominees under Proposal 1 were elected at the annual meeting of stockholders held on May 7, 2026 to serve until the company's next annual meeting of stockholders and until their respective successors are duly elected and qualified. For example, Leslie C. Davis received 461,819,765 votes for and 13,184,241 votes against.
The company said the advisory proposal regarding named executive officer compensation was approved with 424,961,639 votes for and 50,924,101 votes against. It added that the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with 446,283,142 votes for and 56,814,075 votes against.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Long-Term Stock Incentive Program Share Limit Increase Approved
Edwards Lifesciences said stockholders approved the amendment and restatement of its Long-Term Stock Incentive Compensation Program at the 2026 Annual Meeting of Stockholders. The total number of shares of Edwards common stock available for issuance under the program increased by 7,000,000 shares to a new total share limit of 341,500,000 shares.
Source · Based on the filing body and exhibits
Program Amendment Vote Results
The company disclosed voting results on Proposal 4, the approval of the Amended and Restated Long-Term Stock Incentive Compensation Program, with 456,675,201 votes for, 19,210,539 votes against, 0 abstentions and 27,211,476 broker non-votes.
Source · Based on the filing body and exhibits
All 9 Director Nominees Elected
Edwards Lifesciences said all 9 director nominees under Proposal 1 were elected at the annual meeting of stockholders held on May 7, 2026 to serve until the company's next annual meeting of stockholders and until their respective successors are duly elected and qualified. For example, Leslie C. Davis received 461,819,765 votes for and 13,184,241 votes against.
Source · Based on the filing body and exhibits
Named Executive Officer Compensation Advisory Vote and Auditor Appointment Approved
The company said the advisory proposal regarding named executive officer compensation was approved with 424,961,639 votes for and 50,924,101 votes against. It added that the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with 446,283,142 votes for and 56,814,075 votes against.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…